Skip to main content
. 2023 Feb 8;13:1094123. doi: 10.3389/fonc.2023.1094123

Figure 2.

Figure 2

SHP2 inhibitor synergizes with KRASG12C inhibitor in KRAS-G12C-driven NSCLC cell lines. (A) Murine cell lines driven by KRASG12C were plated at 100 cells per well in a 96 well plate and treated with increasing concentrations of either MRTX-1257, RMC-4550, or in combination for 7-10 days, and then assessed for cell growth via CyQuant cell growth assays. HSA synergy was calculated using Combenefit software. (B) LLC 46 NRAS KO, CMT-KRAS-G12C.54 and mKRC.1 cells were seeded in 24-well plates and treated with DMSO diluent, 10 nM MRTX-1257, 300 nM RMC-4550 or the combination. Cell numbers were directly counted on days 1-3 following drug addition. The data are the means and SEM of triplicates. (C) LLC 46 NRAS KO and mKRC.1 cells were plated and treated with DMSO control, MRTX-1257 (100 nM), RMC-4550 (100 nM), or the combination for 2, 6, and 24 hours. Cell lysates were collected and immunoblotted for phospho-ERK, total ERK1/2 protein, PARP and β-actin.